Demir, Seray and Pitarokoili, Kalliopi and Linker, Ralf and Gold, Ralf (2019) Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model. JOURNAL OF NEUROIMMUNOLOGY, 328. pp. 78-85. ISSN 0165-5728, 1872-8421
Full text not available from this repository. (Request a copy)Abstract
The murine anti-CD52 antibody, an equivalent of the humanized antibody alemtuzumab, which is successfully used in the treatment of multiple sclerosis, was used to explore a potential neuroprotective effect driven by immune cell derived brain-derived neurotrophic factor (BDNF). Therefore, lineage specific constitutive knockout mice with a BDNF deficiency in T cells and macrophages were used and compared to treated wildtype mice. Neither therapeutic nor preventive application of the murine anti-CD52 antibody in an animal model of multiple sclerosis, the MOG(35-55) EAE, revealed a beneficial contribution of immune cell derived BDNF to the disease outcome. Furthermore, preventive application of the murine anti-CD52 antibody worsened the clinical EAE disease course and could only be overcome by a prolonged recovery phase after treatment and before disease induction.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MULTIPLE-SCLEROSIS; T-CELLS; ALEMTUZUMAB; Multiple sclerosis; Monoclonal antibodies; Experimental autoimmune encephalomyelitis; Autoimmunity; Alemtuzumab; Immunotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 15 Apr 2020 11:13 |
| Last Modified: | 15 Apr 2020 11:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27361 |
Actions (login required)
 |
View Item |
